Ask OpenScientist

Ask a research question about Autosomal Dominant Osteopetrosis Type II. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
3
Pathophys.
11
Phenotypes
3
Pathograph
2
Genes
2
Treatments
4
References
1
Deep Research
👪

Inheritance

1
Autosomal Dominant
Autosomal dominant with incomplete penetrance (66%) and variable expressivity. Heterozygous CLCN7 mutations exert a dominant negative effect on the chloride channel dimer. Unaffected gene carriers show increased bone mineral density without clinical disease.
Show evidence (1 reference)
PMID:12929941 SUPPORT
"disease penetrance was 66% (62 clinically affected individuals/94 subjects with the gene mutation)"
Demonstrates incomplete penetrance of 66% in the largest ADO2 cohort.

Pathophysiology

3
CLCN7 Dominant Negative Chloride Channel Dysfunction
CLCN7 encodes a chloride channel that functions as a homodimer. Heterozygous missense mutations exert a dominant negative effect by incorporating mutant subunits into the dimer, impairing chloride transport. Loss-of-function (null) mutations in heterozygous state do not cause disease, confirming that the pathogenic mechanism is dominant negative rather than haploinsufficiency.
Osteoclast link
Show evidence (3 references)
PMID:11741829 SUPPORT
"seven different mutations in the gene encoding the ClCN7 chloride channel in all 12 ADO II families analysed"
Identifies CLCN7 as the causative gene for ADO2.
PMID:11741829 SUPPORT
"ADO II reflects a dominant negative effect, whereas loss-of-function mutations in ClCN7 do not cause abnormalities in heterozygous individuals"
Establishes the dominant negative mechanism for CLCN7 missense mutations in ADO2.
PMID:12929941 SUPPORT
"Based on the preponderance of missense mutations and the knowledge that chloride channels probably function as dimers, it seems that heterozygous ClCN7 gene mutations may cause ADO2 through a dominant negative mechanism"
Proposes that dimeric channel structure enables dominant negative pathogenesis.
Impaired Resorption Lacuna Acidification
Dysfunctional CLCN7 chloride channels reduce the ability of osteoclasts to acidify the resorption lacuna, decreasing bone resorption capacity.
Bone Resorption link
Show evidence (1 reference)
PMID:11741829 SUPPORT
"the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption"
Impaired bone resorption leads to the characteristic increased skeletal mass.
Progressive Skeletal Sclerosis
Progressive accumulation of unresorbed bone leads to generalized skeletal sclerosis with paradoxically brittle bones due to disrupted microarchitecture from impaired remodeling.
Bone Remodeling link
Show evidence (1 reference)
PMID:11741829 SUPPORT
"the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption"
Increased skeletal mass results from progressive bone accumulation.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Dominant Osteopetrosis Type II Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

11
Ear 1
Hearing impairment Hearing impairment (HP:0000365)
Show evidence (1 reference)
PMID:10617161 SUPPORT
"Cranial nerve involvement responsible for hearing loss, bilateral optic atrophy, and/or facial palsy was present in 14 patients but was clearly attributable to ADO II in only 6 cases (16%)."
Directly supports hearing loss as part of the ADO2 cranial nerve phenotype, but the abstract does not provide a hearing-specific frequency.
Eye 1
Visual impairment OCCASIONAL Visual impairment (HP:0000505)
Show evidence (1 reference)
PMID:17164308 SUPPORT
"Visual loss, which typically had its onset in childhood, and bone marrow failure occurred in 19 and 3% of ADO subjects, respectively"
19% visual loss falls in the OCCASIONAL band (5-29%).
Context-specific annotations (1)
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:17164308 SUPPORT
"Visual loss, which typically had its onset in childhood, and bone marrow failure occurred in 19 and 3% of ADO subjects, respectively"
Directly supports childhood onset of visual impairment in ADO2.
Head and Neck 1
Facial palsy Facial palsy (HP:0010628)
Show evidence (1 reference)
PMID:10617161 SUPPORT
"Cranial nerve involvement responsible for hearing loss, bilateral optic atrophy, and/or facial palsy was present in 14 patients but was clearly attributable to ADO II in only 6 cases (16%)."
Directly supports facial palsy as part of the ADO2 cranial nerve phenotype, but the abstract does not provide a facial-palsy-specific frequency.
Immune 1
Osteomyelitis OCCASIONAL Osteomyelitis (HP:0002754)
Show evidence (2 references)
PMID:17164308 SUPPORT
"subjects with ADO had a significantly increased prevalence of fracture (84 vs. 36%; P < 0.0001) and osteomyelitis (16 vs. 0.9%; P < 0.0001)"
16% osteomyelitis prevalence in ADO subjects falls in the OCCASIONAL band (5-29%).
PMID:10617161 SUPPORT
"Nearly two-thirds of patients (64%) had stomatologic manifestations, including mandibular osteomyelitis in 4 patients (11%)."
Adds disease-specific support for mandibular predilection of osteomyelitis in ADO2.
Limbs 1
Erlenmeyer flask deformity Erlenmeyer flask deformity of the femurs (HP:0004975)
Show evidence (1 reference)
PMID:24260721 SUPPORT
"the radiographs revealed generalised osteosclerosis and hallmark radiographic features of ADO type II, that is, "bone-within-bone appearance" and "Erlenmeyer-flask deformity.""
Supports Erlenmeyer-flask deformity as a characteristic ADO2 radiographic finding.
Musculoskeletal 4
Osteopetrosis Osteopetrosis (HP:0011002)
Show evidence (3 references)
PMID:11741829 SUPPORT
"the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption"
Defines ADO2 as the most common osteopetrosis form with increased skeletal mass.
PMID:10617161 SUPPORT
"Type II autosomal dominant osteopetrosis (ADO II, Albers-Schonberg disease) is a genetic condition characterized by generalized osteosclerosis predominating in some skeletal sites such as the spine and pelvis."
Supports generalized osteosclerosis with spine and pelvis predominance as a characteristic ADO2 radiographic phenotype.
PMID:24260721 SUPPORT
"the radiographs revealed generalised osteosclerosis and hallmark radiographic features of ADO type II, that is, "bone-within-bone appearance" and "Erlenmeyer-flask deformity.""
Adds exact PMID-backed support that bone-within-bone appearance is a hallmark ADO2 radiographic manifestation.
Recurrent Fractures VERY_FREQUENT Recurrent fractures (HP:0002757)
Show evidence (2 references)
PMID:17164308 SUPPORT
"subjects with ADO had a significantly increased prevalence of fracture (84 vs. 36%; P < 0.0001)"
84% fracture prevalence falls in the VERY_FREQUENT band (80-99%).
PMID:17164308 SUPPORT
"Severe fractures (defined as > or =10 fractures of any type and/or greater than one hip/femur fracture) were identified only in ADO subjects"
Supports that ADO2 can include clinically important severe fracture burden, not just incidental fractures.
Osteoarthritis OCCASIONAL Osteoarthritis (HP:0002758)
Show evidence (1 reference)
PMID:10617161 SUPPORT
"Hip osteoarthritis developed in 27% of patients and required arthroplasty in 9 of the 16 affected hips."
27% falls in the OCCASIONAL band (5-29%) and shows that hip osteoarthritis is a clinically relevant complication.
Scoliosis OCCASIONAL Scoliosis (HP:0002650)
Show evidence (1 reference)
PMID:10617161 SUPPORT
"Twenty-four percent of patients had thoracic or lumbar scoliosis."
24% falls in the OCCASIONAL band (5-29%).
Other 2
Bone marrow failure VERY_RARE Bone marrow hypocellularity (HP:0005528)
Show evidence (1 reference)
PMID:17164308 SUPPORT
"Visual loss, which typically had its onset in childhood, and bone marrow failure occurred in 19 and 3% of ADO subjects, respectively"
Bone marrow failure affected 3% of ADO subjects, which falls in the VERY_RARE band (<5%).
Sandwich appearance of vertebral bodies Sandwich appearance of vertebral bodies (HP:0004618)
Show evidence (1 reference)
PMID:10617161 SUPPORT
"Our inclusion criterion was presence on radiographs of the spine of vertebral endplate thickening, producing the classic sandwich vertebra appearance."
Directly supports sandwich vertebrae as a hallmark radiographic manifestation of ADO2.
🧬

Genetic Associations

2
CLCN7 Mutations (Causative)
Show evidence (2 references)
PMID:12929941 SUPPORT
"nine different mutations have been discovered in the ClCN7 gene in 22 of 23 ADO2 families studied"
Near-complete genetic homogeneity with CLCN7 mutations in ADO2.
PMID:11741829 SUPPORT
"ADO II is allelic with a subset of ARO cases"
CLCN7 mutations cause both dominant and recessive osteopetrosis depending on zygosity.
CLCN7 (Pathogenic Variants)
Show evidence (1 reference)
"CLCN7 | HGNC:2025 | autosomal dominant osteopetrosis 2 | MONDO:0008156 | AD | Definitive"
ClinGen classifies the CLCN7-autosomal dominant osteopetrosis 2 gene-disease relationship as definitive with autosomal dominant inheritance.
💊

Treatments

2
Supportive Care
Action: supportive care MAXO:0000950
Supportive management is directed at complications such as fractures, osteomyelitis, and cranial nerve deficits.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for affected families, noting incomplete penetrance of 66% and variable expressivity.
{ }

Source YAML

click to show
name: Autosomal Dominant Osteopetrosis Type II
creation_date: '2026-02-13T00:31:42Z'
updated_date: '2026-05-08T16:21:17Z'
category: Mendelian
description: >
  Autosomal dominant osteopetrosis type II (ADO2), also known as Albers-Schonberg
  disease, is the most common form of osteopetrosis. It is caused by heterozygous
  mutations in the CLCN7 chloride channel gene, which acts through a dominant
  negative mechanism since chloride channels function as dimers. The disease has
  incomplete penetrance (66%) and variable expressivity. Clinical features include
  increased skeletal density, recurrent fractures, osteomyelitis (particularly
  mandibular), and cranial nerve complications including visual impairment,
  hearing loss, and facial palsy. CLCN7 mutations also cause autosomal recessive
  osteopetrosis when homozygous, establishing ADO2 as allelic with a subset of
  infantile malignant osteopetrosis.
disease_term:
  preferred_term: autosomal dominant osteopetrosis 2
  term:
    id: MONDO:0008156
    label: autosomal dominant osteopetrosis 2
parents:
- Sclerosing Bone Dysplasias
inheritance:
- name: Autosomal Dominant
  description: >
    Autosomal dominant with incomplete penetrance (66%) and variable expressivity.
    Heterozygous CLCN7 mutations exert a dominant negative effect on the chloride
    channel dimer. Unaffected gene carriers show increased bone mineral density
    without clinical disease.
  evidence:
  - reference: PMID:12929941
    reference_title: "Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II."
    supports: SUPPORT
    snippet: "disease penetrance was 66% (62 clinically affected individuals/94 subjects with the gene mutation)"
    explanation: "Demonstrates incomplete penetrance of 66% in the largest ADO2 cohort."
prevalence:
- population: Autosomal dominant osteopetrosis overall
  percentage: 1 in 20,000 births
  notes: >-
    Exact ADO2-specific prevalence is rarely reported separately. This value is
    retained only as background epidemiology for autosomal dominant
    osteopetrosis overall and should not be interpreted as an ADO2-specific
    prevalence estimate.
  evidence:
  - reference: PMID:37465191
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autosomal dominant osteopetrosis has an incidence of 1 in 20,000 newborns and autosomal recessive one has 1 in 250,000."
    explanation: Review-level epidemiology provides the standard incidence estimate for autosomal dominant osteopetrosis overall, not specifically for ADO2.
pathophysiology:
- name: CLCN7 Dominant Negative Chloride Channel Dysfunction
  description: >
    CLCN7 encodes a chloride channel that functions as a homodimer.
    Heterozygous missense mutations exert a dominant negative effect by
    incorporating mutant subunits into the dimer, impairing chloride
    transport. Loss-of-function (null) mutations in heterozygous state
    do not cause disease, confirming that the pathogenic mechanism is
    dominant negative rather than haploinsufficiency.
  cell_types:
  - preferred_term: Osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  evidence:
  - reference: PMID:11741829
    reference_title: "Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene."
    supports: SUPPORT
    snippet: "seven different mutations in the gene encoding the ClCN7 chloride channel in all 12 ADO II families analysed"
    explanation: "Identifies CLCN7 as the causative gene for ADO2."
  - reference: PMID:11741829
    reference_title: "Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene."
    supports: SUPPORT
    snippet: "ADO II reflects a dominant negative effect, whereas loss-of-function mutations in ClCN7 do not cause abnormalities in heterozygous individuals"
    explanation: "Establishes the dominant negative mechanism for CLCN7 missense mutations in ADO2."
  - reference: PMID:12929941
    reference_title: "Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II."
    supports: SUPPORT
    snippet: "Based on the preponderance of missense mutations and the knowledge that chloride channels probably function as dimers, it seems that heterozygous ClCN7 gene mutations may cause ADO2 through a dominant negative mechanism"
    explanation: "Proposes that dimeric channel structure enables dominant negative pathogenesis."
  downstream:
  - target: Impaired Resorption Lacuna Acidification
    description: >-
      Dominant-negative CLCN7 channel dysfunction impairs osteoclast resorption
      lacuna acidification.
- name: Impaired Resorption Lacuna Acidification
  description: >
    Dysfunctional CLCN7 chloride channels reduce the ability of osteoclasts
    to acidify the resorption lacuna, decreasing bone resorption capacity.
  notes: >-
    ADO2 shows incomplete penetrance and variable expressivity, but penetrance
    data are epidemiologic context rather than direct evidence for lacuna
    acidification.
  biological_processes:
  - preferred_term: Bone Resorption
    term:
      id: GO:0045453
      label: bone resorption
  evidence:
  - reference: PMID:11741829
    reference_title: "Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene."
    supports: SUPPORT
    snippet: "the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption"
    explanation: "Impaired bone resorption leads to the characteristic increased skeletal mass."
  downstream:
  - target: Progressive Skeletal Sclerosis
    description: >-
      Reduced osteoclast acidification decreases bone resorption and drives
      progressive skeletal sclerosis.
- name: Progressive Skeletal Sclerosis
  description: >
    Progressive accumulation of unresorbed bone leads to generalized
    skeletal sclerosis with paradoxically brittle bones due to disrupted
    microarchitecture from impaired remodeling.
  biological_processes:
  - preferred_term: Bone Remodeling
    term:
      id: GO:0046849
      label: bone remodeling
  evidence:
  - reference: PMID:11741829
    reference_title: "Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene."
    supports: SUPPORT
    snippet: "the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption"
    explanation: "Increased skeletal mass results from progressive bone accumulation."
phenotypes:
- name: Osteopetrosis
  description: >
    Generalized osteosclerosis with increased skeletal density, especially in
    the spine and pelvis, is the hallmark radiographic abnormality of ADO2.
    Classic radiographs may also show bone-within-bone appearance.
  phenotype_term:
    preferred_term: Osteopetrosis
    term:
      id: HP:0011002
      label: Osteopetrosis
  evidence:
  - reference: PMID:11741829
    reference_title: "Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene."
    supports: SUPPORT
    snippet: "the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption"
    explanation: "Defines ADO2 as the most common osteopetrosis form with increased skeletal mass."
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Type II autosomal dominant osteopetrosis (ADO II, Albers-Schonberg disease) is a genetic condition characterized by generalized osteosclerosis predominating in some skeletal sites such as the spine and pelvis."
    explanation: "Supports generalized osteosclerosis with spine and pelvis predominance as a characteristic ADO2 radiographic phenotype."
  - reference: PMID:24260721
    reference_title: "Clinical and Radiological Findings of Autosomal Dominant Osteopetrosis Type II: A Case Report."
    supports: SUPPORT
    snippet: "the radiographs revealed generalised osteosclerosis and hallmark radiographic features of ADO type II, that is, \"bone-within-bone appearance\" and \"Erlenmeyer-flask deformity.\""
    explanation: "Adds exact PMID-backed support that bone-within-bone appearance is a hallmark ADO2 radiographic manifestation."
- name: Recurrent Fractures
  description: >
    Fractures are the most prevalent clinical consequence of ADO2, and severe
    fracture patterns are seen only in affected subjects.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Recurrent fractures
    term:
      id: HP:0002757
      label: Recurrent fractures
  evidence:
  - reference: PMID:17164308
    reference_title: "Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation."
    supports: SUPPORT
    snippet: "subjects with ADO had a significantly increased prevalence of fracture (84 vs. 36%; P < 0.0001)"
    explanation: "84% fracture prevalence falls in the VERY_FREQUENT band (80-99%)."
  - reference: PMID:17164308
    reference_title: "Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation."
    supports: SUPPORT
    snippet: "Severe fractures (defined as > or =10 fractures of any type and/or greater than one hip/femur fracture) were identified only in ADO subjects"
    explanation: "Supports that ADO2 can include clinically important severe fracture burden, not just incidental fractures."
- name: Osteomyelitis
  description: >
    Osteomyelitis is an occasional complication of ADO2 and most often affects
    the jaws, particularly the mandible.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Osteomyelitis
    term:
      id: HP:0002754
      label: Osteomyelitis
  evidence:
  - reference: PMID:17164308
    reference_title: "Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation."
    supports: SUPPORT
    snippet: "subjects with ADO had a significantly increased prevalence of fracture (84 vs. 36%; P < 0.0001) and osteomyelitis (16 vs. 0.9%; P < 0.0001)"
    explanation: "16% osteomyelitis prevalence in ADO subjects falls in the OCCASIONAL band (5-29%)."
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Nearly two-thirds of patients (64%) had stomatologic manifestations, including mandibular osteomyelitis in 4 patients (11%)."
    explanation: "Adds disease-specific support for mandibular predilection of osteomyelitis in ADO2."
- name: Visual impairment
  description: >
    Visual impairment or vision loss is an occasional but clinically important
    complication of ADO2.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:17164308
    reference_title: "Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation."
    supports: SUPPORT
    snippet: "Visual loss, which typically had its onset in childhood, and bone marrow failure occurred in 19 and 3% of ADO subjects, respectively"
    explanation: "19% visual loss falls in the OCCASIONAL band (5-29%)."
  phenotype_contexts:
  - onset:
      onset_category: CHILDHOOD
      notes: Visual loss was reported as typically beginning in childhood.
    evidence:
    - reference: PMID:17164308
      reference_title: "Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation."
      supports: SUPPORT
      snippet: "Visual loss, which typically had its onset in childhood, and bone marrow failure occurred in 19 and 3% of ADO subjects, respectively"
      explanation: "Directly supports childhood onset of visual impairment in ADO2."
- name: Hearing impairment
  description: >
    Cranial nerve involvement in ADO2 can include hearing loss, although the
    available abstract evidence does not quantify hearing impairment separately
    from other cranial neuropathies.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Cranial nerve involvement responsible for hearing loss, bilateral optic atrophy, and/or facial palsy was present in 14 patients but was clearly attributable to ADO II in only 6 cases (16%)."
    explanation: "Directly supports hearing loss as part of the ADO2 cranial nerve phenotype, but the abstract does not provide a hearing-specific frequency."
- name: Facial palsy
  description: >
    Facial palsy is part of the cranial nerve complication spectrum of ADO2.
  phenotype_term:
    preferred_term: Facial palsy
    term:
      id: HP:0010628
      label: Facial palsy
  evidence:
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Cranial nerve involvement responsible for hearing loss, bilateral optic atrophy, and/or facial palsy was present in 14 patients but was clearly attributable to ADO II in only 6 cases (16%)."
    explanation: "Directly supports facial palsy as part of the ADO2 cranial nerve phenotype, but the abstract does not provide a facial-palsy-specific frequency."
- name: Bone marrow failure
  description: >
    Bone marrow failure is a rare but clinically important hematologic
    complication of ADO2.
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Bone marrow failure
    term:
      id: HP:0005528
      label: Bone marrow hypocellularity
  evidence:
  - reference: PMID:17164308
    reference_title: "Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation."
    supports: SUPPORT
    snippet: "Visual loss, which typically had its onset in childhood, and bone marrow failure occurred in 19 and 3% of ADO subjects, respectively"
    explanation: "Bone marrow failure affected 3% of ADO subjects, which falls in the VERY_RARE band (<5%)."
- name: Osteoarthritis
  description: >
    Hip-predominant osteoarthritis can complicate ADO2 and may require
    arthroplasty.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
  evidence:
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Hip osteoarthritis developed in 27% of patients and required arthroplasty in 9 of the 16 affected hips."
    explanation: "27% falls in the OCCASIONAL band (5-29%) and shows that hip osteoarthritis is a clinically relevant complication."
- name: Scoliosis
  description: >
    Thoracic or lumbar scoliosis occurs in a minority of patients with ADO2.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Twenty-four percent of patients had thoracic or lumbar scoliosis."
    explanation: "24% falls in the OCCASIONAL band (5-29%)."
- name: Sandwich appearance of vertebral bodies
  description: >
    Vertebral endplate thickening producing a sandwich vertebra appearance is a
    classic radiographic sign of ADO2.
  phenotype_term:
    preferred_term: Sandwich vertebrae
    term:
      id: HP:0004618
      label: Sandwich appearance of vertebral bodies
  evidence:
  - reference: PMID:10617161
    reference_title: "Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients."
    supports: SUPPORT
    snippet: "Our inclusion criterion was presence on radiographs of the spine of vertebral endplate thickening, producing the classic sandwich vertebra appearance."
    explanation: "Directly supports sandwich vertebrae as a hallmark radiographic manifestation of ADO2."
- name: Erlenmeyer flask deformity
  description: >
    Erlenmeyer-flask deformity is part of the hallmark radiographic phenotype of
    ADO2.
  phenotype_term:
    preferred_term: Erlenmeyer flask deformity
    term:
      id: HP:0004975
      label: Erlenmeyer flask deformity of the femurs
  evidence:
  - reference: PMID:24260721
    reference_title: "Clinical and Radiological Findings of Autosomal Dominant Osteopetrosis Type II: A Case Report."
    supports: SUPPORT
    snippet: "the radiographs revealed generalised osteosclerosis and hallmark radiographic features of ADO type II, that is, \"bone-within-bone appearance\" and \"Erlenmeyer-flask deformity.\""
    explanation: "Supports Erlenmeyer-flask deformity as a characteristic ADO2 radiographic finding."
genetic:
- name: CLCN7 Mutations
  association: Causative
  notes: >
    Heterozygous missense mutations in CLCN7 on chromosome 16p13.3.
    Predominantly missense mutations consistent with dominant negative
    mechanism through dimeric channel disruption. Nine different
    mutations identified in 22 of 23 ADO2 families, indicating
    minimal genetic heterogeneity. CLCN7 mutations are allelic with
    autosomal recessive osteopetrosis when homozygous.
  evidence:
  - reference: PMID:12929941
    reference_title: "Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II."
    supports: SUPPORT
    snippet: "nine different mutations have been discovered in the ClCN7 gene in 22 of 23 ADO2 families studied"
    explanation: "Near-complete genetic homogeneity with CLCN7 mutations in ADO2."
  - reference: PMID:11741829
    reference_title: "Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene."
    supports: SUPPORT
    snippet: "ADO II is allelic with a subset of ARO cases"
    explanation: "CLCN7 mutations cause both dominant and recessive osteopetrosis depending on zygosity."
- name: CLCN7
  gene_term:
    preferred_term: CLCN7
    term:
      id: hgnc:2025
      label: CLCN7
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_23840c1f-9d30-4ccf-9fc0-604a0cb12eb4-2023-12-04T170000.000Z
    reference_title: "CLCN7 / autosomal dominant osteopetrosis 2 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLCN7 | HGNC:2025 | autosomal dominant osteopetrosis 2 | MONDO:0008156 | AD | Definitive"
    explanation: ClinGen classifies the CLCN7-autosomal dominant osteopetrosis 2 gene-disease relationship as definitive with autosomal dominant inheritance.
treatments:
- name: Supportive Care
  description: >
    Supportive management is directed at complications such as fractures,
    osteomyelitis, and cranial nerve deficits.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Genetic Counseling
  description: >
    Genetic counseling for affected families, noting incomplete
    penetrance of 66% and variable expressivity.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
references:
- reference: DOI:10.1093/jbmr/zjaf123
  title: Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis
  found_in:
  - Autosomal_Dominant_Osteopetrosis_Type_II-deep-research-falcon.md
  findings:
  - statement: Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption.
    supporting_text: Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption.
    evidence:
    - reference: DOI:10.1093/jbmr/zjaf123
      reference_title: Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption.
      explanation: Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
- reference: DOI:10.18699/vjgb-23-46
  title: Clinical, genetic aspects and molecular pathogenesis of osteopetrosis
  found_in:
  - Autosomal_Dominant_Osteopetrosis_Type_II-deep-research-falcon.md
  findings:
  - statement: Osteopetrosis (“marble bone”, ICD-10-78.2) includes a group of hereditary bone disorders distinguished by clinical variability and genetic heterogeneity.
    supporting_text: Osteopetrosis (“marble bone”, ICD-10-78.2) includes a group of hereditary bone disorders distinguished by clinical variability and genetic heterogeneity.
    evidence:
    - reference: DOI:10.18699/vjgb-23-46
      reference_title: Clinical, genetic aspects and molecular pathogenesis of osteopetrosis
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Osteopetrosis (“marble bone”, ICD-10-78.2) includes a group of hereditary bone disorders distinguished by clinical variability and genetic heterogeneity.
      explanation: Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
- reference: DOI:10.3389/fendo.2022.819641
  title: 'Natural History of Type II Autosomal Dominant Osteopetrosis: A Single Center Retrospective Study'
  found_in:
  - Autosomal_Dominant_Osteopetrosis_Type_II-deep-research-falcon.md
  findings:
  - statement: Autosomal dominant osteopetrosis II (ADO II, MIM166600) is a sclerosing bone disorder caused by CLCN7 mutation.
    supporting_text: Autosomal dominant osteopetrosis II (ADO II, MIM166600) is a sclerosing bone disorder caused by CLCN7 mutation.
    evidence:
    - reference: DOI:10.3389/fendo.2022.819641
      reference_title: 'Natural History of Type II Autosomal Dominant Osteopetrosis: A Single Center Retrospective Study'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Autosomal dominant osteopetrosis II (ADO II, MIM166600) is a sclerosing bone disorder caused by CLCN7 mutation.
      explanation: Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
- reference: DOI:10.3390/ijms241210412
  title: Molecular Mechanisms of Craniofacial and Dental Abnormalities in Osteopetrosis
  found_in:
  - Autosomal_Dominant_Osteopetrosis_Type_II-deep-research-falcon.md
  findings:
  - statement: Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption.
    supporting_text: Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption.
    evidence:
    - reference: DOI:10.3390/ijms241210412
      reference_title: Molecular Mechanisms of Craniofacial and Dental Abnormalities in Osteopetrosis
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption.
      explanation: Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
📚

References & Deep Research

References

4
Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis
1 finding
Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption.
"Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption."
Show evidence (1 reference)
DOI:10.1093/jbmr/zjaf123 SUPPORT Human Clinical
"Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption."
Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
Clinical, genetic aspects and molecular pathogenesis of osteopetrosis
1 finding
Osteopetrosis (“marble bone”, ICD-10-78.2) includes a group of hereditary bone disorders distinguished by clinical variability and genetic heterogeneity.
"Osteopetrosis (“marble bone”, ICD-10-78.2) includes a group of hereditary bone disorders distinguished by clinical variability and genetic heterogeneity."
Show evidence (1 reference)
DOI:10.18699/vjgb-23-46 SUPPORT Human Clinical
"Osteopetrosis (“marble bone”, ICD-10-78.2) includes a group of hereditary bone disorders distinguished by clinical variability and genetic heterogeneity."
Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
Natural History of Type II Autosomal Dominant Osteopetrosis: A Single Center Retrospective Study
1 finding
Autosomal dominant osteopetrosis II (ADO II, MIM166600) is a sclerosing bone disorder caused by CLCN7 mutation.
"Autosomal dominant osteopetrosis II (ADO II, MIM166600) is a sclerosing bone disorder caused by CLCN7 mutation."
Show evidence (1 reference)
DOI:10.3389/fendo.2022.819641 SUPPORT Human Clinical
"Autosomal dominant osteopetrosis II (ADO II, MIM166600) is a sclerosing bone disorder caused by CLCN7 mutation."
Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.
Molecular Mechanisms of Craniofacial and Dental Abnormalities in Osteopetrosis
1 finding
Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption.
"Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption."
Show evidence (1 reference)
"Osteopetrosis is a group of genetic bone disorders characterized by increased bone density and defective bone resorption."
Deep research cited this publication as relevant literature for Autosomal Dominant Osteopetrosis Type II.

Deep Research

1
Falcon
Autosomal Dominant Osteopetrosis Type II (ADO2) — Comprehensive Disease Characteristics Report
Edison Scientific Literature 24 citations 2026-05-08T08:09:04.551073

Autosomal Dominant Osteopetrosis Type II (ADO2) — Comprehensive Disease Characteristics Report

Target Disease

  • Disease name: Autosomal Dominant Osteopetrosis Type II (ADO2)
  • Category: Mendelian (autosomal dominant)
  • MONDO ID: MONDO:0008156 (“autosomal dominant osteopetrosis 2”) (OpenTargets Search: autosomal dominant osteopetrosis type II,Albers-Schönberg disease-CLCN7)

1. Disease Information

1.1 Definition / overview

Autosomal dominant osteopetrosis type II (ADO2) is a rare high–bone-mass skeletal disorder caused by impaired osteoclast-mediated bone resorption, leading to radiographically dense but mechanically fragile bone with frequent fractures and characteristic imaging findings (e.g., “sandwich vertebrae” and “bone-in-bone”). It is also referred to as Albers–Schönberg disease and is described as the commonest adult form of osteopetrosis (funckbrentanoUnknownyearppelmandikstranm pages 1-3, funckbrentanoUnknownyearppelmandikstranm pages 3-4, kang2019acaseof pages 1-3).

Current understanding (key concept): Osteopetrosis represents a group of disorders in which osteoclast formation/function is impaired, resulting in increased bone mass but compromised bone quality, with downstream complications including fractures, cranial nerve compression, and (less commonly in ADO2) marrow compromise (funckbrentanoUnknownyearppelmandikstranm pages 1-3, nadyrshina2023clinicalgeneticaspects pages 2-3).

1.2 Key identifiers

  • OMIM/MIM: MIM 166600 (ADO2) (wang2022naturalhistoryof pages 1-2)
  • MONDO: MONDO:0008156 (OpenTargets Search: autosomal dominant osteopetrosis type II,Albers-Schönberg disease-CLCN7)
  • ICD-10: Osteopetrosis is listed as ICD-10-78.2 in a 2023 review (note: this is for osteopetrosis as a category; ADO2-specific ICD granularity was not captured in retrieved evidence) (nadyrshina2023clinicalgeneticaspects pages 1-2)
  • Orphanet / MeSH / ICD-11: Not available in the retrieved full-text evidence set; should be filled from Orphanet/MeSH/ICD-11 directly.

1.3 Common synonyms / alternative names

  • Autosomal dominant osteopetrosis type II
  • ADO II / ADO2
  • Albers–Schönberg disease (funckbrentanoUnknownyearppelmandikstranm pages 1-3, kang2019acaseof pages 1-3)

1.4 Source type of information

This report integrates: - Aggregated resources and expert reviews (2023–2024) (funckbrentanoUnknownyearppelmandikstranm pages 1-3, nadyrshina2023clinicalgeneticaspects pages 1-2, ma2023molecularmechanismsof pages 2-4) - Human cohort / natural history studies (2022; plus a later natural-history biomarker report) (wang2022naturalhistoryof pages 1-2, wang2022naturalhistoryof pages 8-9, econs2026fracturesarehighly pages 1-3) - Case reports (illustrating variable expressivity and reduced penetrance) (kang2019acaseof pages 1-3) - Model organism and mechanistic synthesis (mouse models; craniofacial/dental mechanisms) (ma2023molecularmechanismsof pages 2-4, ma2023molecularmechanismsof pages 8-10)


2. Etiology

2.1 Disease causal factors

Primary cause: germline heterozygous pathogenic variants in CLCN7 (Cl−/H+ antiporter 7; historically described as a “chloride channel”), causing osteoclast dysfunction with impaired resorption lacuna acidification (wang2022naturalhistoryof pages 1-2, funckbrentanoUnknownyearppelmandikstranm pages 1-3, funckbrentanoUnknownyearppelmandikstranm pages 3-4). A 2024 adult osteopetrosis review notes that “more than 34 CLCN7 mutations have been reported” in ADO (funckbrentanoUnknownyearppelmandikstranm pages 1-3).

Key mechanistic etiologic statement (quoted):Mutation in CLCN7 may disrupt acidification of the osteoclast resorption lacunae, resulting in impaired bone degradation” (ADO II, MIM166600) (wang2022naturalhistoryof pages 1-2).

Additional required component: The OSTM1 subunit is described as required for ClC-7/CLCN7 trafficking to the osteoclast ruffled border (funckbrentanoUnknownyearppelmandikstranm pages 1-3, funckbrentanoUnknownyearppelmandikstranm pages 3-4).

2.2 Risk factors

  • Genetic: carrying a pathogenic CLCN7 variant is the principal risk factor (Mendelian causal). Penetrance is incomplete and expressivity is variable (funckbrentanoUnknownyearppelmandikstranm pages 3-4, econs2026fracturesarehighly pages 1-3).
  • Non-genetic/environmental: The retrieved evidence did not identify consistent environmental risk factors for ADO2 onset; clinical risk is dominated by genotype.

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No specific gene–environment interactions were identified in the retrieved evidence.


3. Phenotypes

3.1 Core clinical phenotypes (with characteristics)

Skeletal fragility/fracture (symptom/sign): - Fracture is a defining complication despite very high BMD (funckbrentanoUnknownyearppelmandikstranm pages 3-4, wang2022naturalhistoryof pages 8-9). - In a Chinese cohort (n=36), fracture frequency was 55.6% (20/36) (wang2022naturalhistoryof pages 8-9). - A 2024 review summarizes fractures in ~46% of patients and notes delayed healing (funckbrentanoUnknownyearppelmandikstranm pages 3-4). - Fracture risk is not reliably predicted by BMD in at least one follow-up subset: BMD stable over ~6 years, yet 5/15 sustained new fractures (funckbrentanoUnknownyearppelmandikstranm pages 3-4, wang2022naturalhistoryof pages 5-6).

Delayed fracture healing (clinical course): - Fractures may show delayed consolidation, sometimes “months to years” per adult osteopetrosis review (funckbrentanoUnknownyearppelmandikstranm pages 3-4).

Osteomyelitis (especially mandibular) / dental infection: - Mandibular osteomyelitis is highlighted as a difficult complication requiring prolonged treatment (funckbrentanoUnknownyearppelmandikstranma pages 4-5).

Cranial nerve compression / skull-base complications: - Vision loss, hearing loss, and facial palsy can occur from skull base sclerosis and foraminal narrowing (wang2022naturalhistoryof pages 8-9, funckbrentanoUnknownyearppelmandikstranma pages 4-5, nadyrshina2023clinicalgeneticaspects pages 2-3). - In the Chinese cohort, visual loss was 1/36 and bone marrow failure 2/36 (wang2022naturalhistoryof pages 1-2).

Degenerative joint disease / hip osteoarthritis: - Hip osteoarthritis and joint discomfort are reported clinical characteristics (wang2022naturalhistoryof pages 1-2, wang2022naturalhistoryof pages 5-6).

Hematologic features (less common in ADO2): - Reduced marrow space can contribute to anemia/hepatosplenomegaly in osteopetrosis broadly; adult ADO2 marrow failure is noted as uncommon but possible (funckbrentanoUnknownyearppelmandikstranm pages 3-4, nadyrshina2023clinicalgeneticaspects pages 2-3).

3.2 Craniofacial and dental phenotypes (2023 synthesis)

A 2023 craniofacial/dental review explicitly catalogs craniofacial and dental abnormalities across osteopetrosis subtypes and includes ADO2/OPTA2 (OMIM #166600). It emphasizes that ion channels/transporters including TCIRG1, CLCN7, OSTM1, SLC4A2may control osteoclastic acidification” (ma2023molecularmechanismsof pages 1-2). It also recommends dental attention to prevent missed diagnoses: “It is recommended that dentists pay attention to the craniofacial condition of osteopetrosis patients to reduce missed diagnoses” (ma2023molecularmechanismsof pages 12-13).

3.3 Suggested HPO terms (non-exhaustive)

(IDs should be verified against current HPO release during KB ingestion.) - Increased bone mineral density / osteosclerosis (e.g., Osteosclerosis) - Pathologic fracture / recurrent fractures - Delayed fracture healing - Osteomyelitis of the jaw / mandibular osteomyelitis - Visual impairment / optic atrophy (optic canal narrowing mechanism noted) (wang2022naturalhistoryof pages 8-9) - Hearing impairment - Facial palsy - Dental anomalies: delayed tooth eruption, hypodontia/dental agenesis, caries, malocclusion (funckbrentanoUnknownyearppelmandikstranma pages 4-5, ma2023molecularmechanismsof pages 8-10)

3.4 Quality of life impacts

Direct QoL instrument data (e.g., SF-36, PROMIS) were not present in the retrieved evidence set; however, fracture burden, chronic osteomyelitis, and sensory impairment are expected to be major drivers of disability (funckbrentanoUnknownyearppelmandikstranm pages 1-3, funckbrentanoUnknownyearppelmandikstranm pages 3-4).


4. Genetic / Molecular Information

4.1 Causal gene(s)

  • CLCN7 (Cl−/H+ antiporter 7) is the principal ADO2 gene (funckbrentanoUnknownyearppelmandikstranm pages 1-3, wang2022naturalhistoryof pages 1-2, OpenTargets Search: autosomal dominant osteopetrosis type II,Albers-Schönberg disease-CLCN7).

4.2 Pathogenic variants and genotype–phenotype

Variant spectrum and frequencies (cohort-level): In a single-center Chinese cohort (n=36), 21 disease-causing CLCN7 mutations were detected (wang2022naturalhistoryof pages 5-6). - c.2299C>T (p.Arg767Trp): 16.2% - c.296A>G (p.Tyr99Cys): 10.8% - c.857G>A (p.Arg286Gln): 10.8% - c.937G>A (p.Glu313Lys): 8.1% (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 8-9)

Reported genotype–phenotype link (example): c.937G>A (p.Glu313Lys) was associated with “severe fractures, haematological defects and cranial palsy” in this cohort (wang2022naturalhistoryof pages 1-2).

Penetrance / expressivity: - Incomplete penetrance (~66% symptomatic carriers) (funckbrentanoUnknownyearppelmandikstranm pages 3-4, funckbrentanoUnknownyearppelmandikstranm pages 1-3) - Penetrance estimate 69.23% in one cohort (wang2022naturalhistoryof pages 2-3) - Familial penetrance reported range 60–90% in a case report review (kang2019acaseof pages 1-3)

Expert interpretation: A later natural-history biomarker study emphasizes marked intrafamilial variability and reports no significant phenotype differences between the most common variant in that cohort (G215R) vs other variants across fracture/BMD/biochemical markers (econs2026fracturesarehighly pages 1-3).

4.3 Modifier genes / protective variants

No validated modifier genes or protective variants specific to ADO2 were identified in the retrieved evidence.

4.4 Epigenetics / chromosomal abnormalities

Not identified for ADO2 in the retrieved evidence.


5. Environmental Information

No disease-specific environmental, lifestyle, or infectious triggers were identified in the retrieved evidence set. Clinical risks in ADO2 are primarily genetically determined.


6. Mechanism / Pathophysiology

6.1 Causal chain (genotype → cellular defect → clinical manifestations)

  1. Trigger: Germline heterozygous CLCN7 pathogenic variant (wang2022naturalhistoryof pages 1-2).
  2. Upstream cellular mechanism: Disruption of osteoclast acidification/resorption lacuna function; impaired ruffled border function/trafficking (including requirement for OSTM1) (funckbrentanoUnknownyearppelmandikstranm pages 3-4, funckbrentanoUnknownyearppelmandikstranm pages 1-3).
  3. Tissue-level consequences: Failure to resorb mineralized bone and calcified cartilage → osteosclerosis/high bone mass with abnormal microarchitecture (“bone islets”; persistent calcified cartilage as a hallmark of osteoclast failure) (funckbrentanoUnknownyearppelmandikstranm pages 4-5, funckbrentanoUnknownyearppelmandikstranma pages 4-5).
  4. Clinical phenotype: Dense but brittle bone with frequent fractures and delayed repair; skull base sclerosis with foraminal narrowing and cranial neuropathies; mandibular/dental complications; occasional marrow space compromise (funckbrentanoUnknownyearppelmandikstranm pages 3-4, funckbrentanoUnknownyearppelmandikstranma pages 4-5, nadyrshina2023clinicalgeneticaspects pages 2-3).

6.2 Pathways and molecular components

A 2023 craniofacial/dental mechanisms review describes core acidification machinery: CA2 generates H+; V-ATPase pumps H+; CLCN7/OSTM1 functions as a 2Cl−/H+ antiporter contributing to acidification and resorption processes; SLC4A2 supports Cl− flux and downstream protease activation and cytoskeletal/podosome dynamics (ma2023molecularmechanismsof pages 8-10).

6.3 Biomarkers / biochemical abnormalities

  • TRAP5b: A 2024 review states “TRAP5b levels are always above the normal range in ADO” and recommends monitoring (funckbrentanoUnknownyearppelmandikstranma pages 4-5).
  • A natural history biomarker study (n=54) found correlations with fracture burden: TRAP correlated positively with fractures (r=0.52), while resorption markers CTX and NTx/Cr correlated inversely (econs2026fracturesarehighly pages 1-3).

6.4 Cell types (Cell Ontology suggestions)

  • Osteoclast (primary effector cell; CL term: osteoclast)
  • Osteoblast/osteocyte (secondary remodeling context)

6.5 GO term suggestions (verify IDs during curation)

  • Bone resorption
  • Osteoclast differentiation
  • Proton transmembrane transport / lysosomal acidification
  • Chloride transmembrane transport

6.6 -omics / advanced technologies

  • Human iPSC disease modeling exists for ADO2 and includes proteomic profiling of patient-derived iPSCs (Ou et al., 2019; not a 2023–2024 development but a relevant real-world model platform) (ou2019genotypinggenerationand…; see retrieved corpus).

7. Anatomical Structures Affected

7.1 Organ/system level

  • Skeletal system (primary): spine, pelvis, long bones, skull base (funckbrentanoUnknownyearppelmandikstranm pages 3-4, wang2022naturalhistoryof pages 8-9)
  • Cranial nerve pathways (secondary): optic canal narrowing with optic atrophy; auditory/facial nerve impingement (wang2022naturalhistoryof pages 8-9, funckbrentanoUnknownyearppelmandikstranma pages 4-5)
  • Orofacial/dental: mandible and dentition (osteomyelitis, dental anomalies) (funckbrentanoUnknownyearppelmandikstranma pages 4-5, ma2023molecularmechanismsof pages 8-10)
  • Hematopoietic system (variable/less common in ADO2 adults): marrow space compromise and cytopenias in more severe cases (funckbrentanoUnknownyearppelmandikstranm pages 3-4, wang2022naturalhistoryof pages 1-2)

7.2 UBERON suggestions (verify IDs)

  • Bone of vertebral column; lumbar vertebra
  • Pelvic bone
  • Skull base
  • Mandible
  • Bone marrow

8. Temporal Development (Natural History)

  • Typical onset: late childhood/adolescence to adulthood (ADO described as milder/benign adult form) (nadyrshina2023clinicalgeneticaspects pages 1-2, ma2023molecularmechanismsof pages 2-4).
  • Course: Often described as relatively stable; however, fractures can occur repeatedly, and fracture healing may be prolonged (funckbrentanoUnknownyearppelmandikstranm pages 3-4, wang2022naturalhistoryof pages 1-2).
  • In a retrospective cohort with follow-up (mean ~6.3 years), incident fractures occurred despite stable BMD (funckbrentanoUnknownyearppelmandikstranm pages 3-4, wang2022naturalhistoryof pages 5-6).

9. Inheritance and Population

9.1 Inheritance

  • Autosomal dominant with incomplete penetrance and variable expressivity (funckbrentanoUnknownyearppelmandikstranm pages 3-4, kang2019acaseof pages 1-3).

9.2 Epidemiology

  • Incidence estimate: ~1 in 20,000 births reported for ADO in multiple reviews/studies (funckbrentanoUnknownyearppelmandikstranm pages 1-3, nadyrshina2023clinicalgeneticaspects pages 1-2, econs2026fracturesarehighly pages 1-3).
  • A 2023 craniofacial/dental review cites a frequency ~5.5 per 100,000 for OPTA2/ADO2 (ma2023molecularmechanismsof pages 2-4).

Demographics: A Chinese cohort reports fractures often occurring at ≤18 years among those who fracture (age distribution for fractures presented as “≤18/>18: 37/7”) (wang2022naturalhistoryof pages 8-9). Sex ratio and geographic/ancestry enrichment were not available in the retrieved evidence.


10. Diagnostics

10.1 Clinical criteria and imaging

Radiographic hallmarks (diagnostic cornerstone): - “Sandwich vertebrae”/vertebral endplate sclerosis; “bone-in-bone” appearances; skull base densification; Erlenmeyer-flask changes (funckbrentanoUnknownyearppelmandikstranm pages 3-4, funckbrentanoUnknownyearppelmandikstranma pages 4-5).

Imaging for complications: MRI/CT/tomodensitometry to monitor optic foramina and cranial nerve compression (funckbrentanoUnknownyearppelmandikstranm pages 3-4).

10.2 DXA and bone density

DXA typically shows markedly increased BMD (e.g., Z-score > +2), but BMD may not reliably predict fracture risk and routine serial BMD is not recommended for fracture-risk monitoring by one expert review (funckbrentanoUnknownyearppelmandikstranm pages 3-4).

10.3 Laboratory evaluation / biomarkers

  • Suggested monitoring includes blood count and PTH (funckbrentanoUnknownyearppelmandikstranma pages 4-5).
  • TRAP5b may be elevated and is suggested as a useful marker of osteoclast number in ADO (funckbrentanoUnknownyearppelmandikstranma pages 4-5).

10.4 Genetic testing

A cohort states: “The diagnosis of ADOII depends on clinical manifestations, typical imaging examinations and CLCN7 gene mutation” (wang2022naturalhistoryof pages 2-3). Practical approach: targeted CLCN7 testing or broader skeletal dysplasia/osteoclast disorder panels or exome sequencing depending on context.

10.5 Differential diagnosis

Not comprehensively captured in retrieved evidence; key clinical differentials include other osteosclerotic disorders and other osteopetrosis genetic subtypes (e.g., LRP5-driven OPTA1; recessive TCIRG1/OSTM1 forms), which differ in severity, hematologic involvement, and transplant responsiveness (nadyrshina2023clinicalgeneticaspects pages 2-3, ma2023molecularmechanismsof pages 12-13).


11. Outcome / Prognosis

  • ADO2 is generally considered milder than infantile recessive osteopetrosis, but morbidity can be substantial due to fracture burden and cranial/dental complications (nadyrshina2023clinicalgeneticaspects pages 1-2, funckbrentanoUnknownyearppelmandikstranm pages 1-3).
  • In one cohort, severe outcomes (visual loss 1/36; marrow failure 2/36) were uncommon but present (wang2022naturalhistoryof pages 1-2).

Quantitative survival/life expectancy statistics specific to ADO2 were not available in the retrieved evidence set.


12. Treatment

12.1 Current applications and real-world implementations (adult ADO2)

Consensus from adult osteopetrosis expert review: Adult ADO2 care is largely supportive and multidisciplinary, ideally in specialized centers, focusing on monitoring and managing fractures, dental/mandibular infections, and cranial nerve complications (funckbrentanoUnknownyearppelmandikstranm pages 1-3, funckbrentanoUnknownyearppelmandikstranma pages 4-5).

Examples of real-world management needs: - Mandibular osteomyelitis may require “long-term antibiotic therapy and surgical debridement” (funckbrentanoUnknownyearppelmandikstranma pages 4-5). - Skull base/cranial foramina involvement may require specialized ophthalmologic/ENT monitoring and, in some cases, surgical decompression or neurosurgical intervention (funckbrentanoUnknownyearppelmandikstranma pages 4-5).

12.2 HSCT (contextual, not typical for adult ADO2)

A 2023 review notes HSCT “is recognized as the most effective treatment, which allows restoration of bone resorption by cells of donor origin,” but also emphasizes genotype-specific contraindications (e.g., severe neurological disorders in TNFSF11/OSTM1) (nadyrshina2023clinicalgeneticaspects pages 2-3). Adult ADO2 (CLCN7) is generally managed conservatively rather than transplanted in the reviewed expert summary (funckbrentanoUnknownyearppelmandikstranm pages 1-3).

12.3 Experimental / emerging (research directions)

Expert reviews emphasize knowledge gaps and the need for therapies that restore osteoclast resorptive capacity and for better natural history/endpoint development (funckbrentanoUnknownyearppelmandikstranm pages 1-3, econs2026fracturesarehighly pages 1-3).

12.4 MAXO term suggestions (verify IDs)

  • Orthopedic fracture management
  • Surgical debridement (mandibular osteomyelitis)
  • Long-term antibiotic therapy
  • Ophthalmologic monitoring; ENT monitoring
  • Genetic counseling

13. Prevention

No primary prevention exists for a Mendelian causal disorder; practical prevention is tertiary prevention of complications via surveillance and prompt management: - Prevent/manage dental infection and avoid high-risk dental trauma when possible; early referral for mandibular infection (funckbrentanoUnknownyearppelmandikstranma pages 4-5, ma2023molecularmechanismsof pages 12-13) - Monitor for cranial nerve compromise (vision/hearing) (funckbrentanoUnknownyearppelmandikstranma pages 4-5) - Genetic counseling for affected families due to AD inheritance and incomplete penetrance (kang2019acaseof pages 1-3)


14. Other Species / Natural Disease

No naturally occurring veterinary ADO2 analogs were identified in the retrieved evidence set.


15. Model Organisms

  • Mouse (Clcn7-deficient models): described as recapitulating high bone density and multisystem phenotypes including neurodegeneration and dental/retinal abnormalities, supporting mechanistic relevance for CLCN7-dependent osteopetrosis (ma2023molecularmechanismsof pages 2-4).
  • Myeloid cell-specific Clcn7 mutant mouse (e.g., Clcn7G763R): used to validate pathway-level findings in CLCN7-mutant osteopetrosis research (basit2026geneticsofosteopetrosis pages 8-9).
  • Human iPSC models: ADO2-specific iPSCs with proteomic profiling exist, enabling disease modeling and therapeutic screening (Ou et al., 2019; see retrieved corpus).

Key quantitative evidence summary (for KB ingestion)

The following table consolidates incidence, penetrance, fracture burden, and recurrent CLCN7 variant frequencies and phenotype notes.

Finding Value Population/Study Year PMID/DOI/URL Evidence ID
Estimated incidence of ADO/ADO2 ~1 in 20,000 births Adult osteopetrosis review; ADO2/Albers–Schönberg disease described as the common adult form 2024 Eur J Med Genet review URL not fully available in context; OpenTargets disease mapping available: https://platform.opentargets.org/disease/MONDO_0008156 (funckbrentanoUnknownyearppelmandikstranm pages 1-3, OpenTargets Search: autosomal dominant osteopetrosis type II,Albers-Schönberg disease-CLCN7)
Penetrance of CLCN7-associated ADO2 ~66% symptomatic carriers Review summary of mutation carriers with incomplete penetrance 2024 Review URL not fully available in context (funckbrentanoUnknownyearppelmandikstranm pages 3-4, funckbrentanoUnknownyearppelmandikstranm pages 1-3)
Penetrance in single-center Chinese cohort 69.23% 36 patients from 28 unrelated families with ADOII 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 2-3)
Penetrance range reported in families 60–90% Family/case-based literature summarized in Korean case report 2019 DOI: 10.4274/jcrpe.galenos.2019.2018.0229; https://doi.org/10.4274/jcrpe.galenos.2019.2018.0229 (kang2019acaseof pages 1-3)
Overall fracture frequency in ADO2 ~46% Review summary of ADO2 patients 2024 Review URL not fully available in context (funckbrentanoUnknownyearppelmandikstranm pages 3-4, funckbrentanoUnknownyearppelmandikstranma pages 3-4)
Fracture frequency in Chinese ADO2 cohort 55.6% (20/36) 36 Chinese patients with ADO II 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 8-9)
Fracture frequency by age group in prior series 53% affected children; 98% affected adults Prior ADO cohort summarized in natural-history/biomarker study 2026 DOI: 10.1093/jbmr/zjaf123; https://doi.org/10.1093/jbmr/zjaf123 (econs2026fracturesarehighly pages 8-10)
Severe fractures by age group in prior series 16% children; 49% adults Prior ADO cohort summarized in natural-history/biomarker study 2026 DOI: 10.1093/jbmr/zjaf123; https://doi.org/10.1093/jbmr/zjaf123 (econs2026fracturesarehighly pages 8-10)
Fracture frequency in Benichou series 78% 42 ADO patients summarized in biomarker study 2026 DOI: 10.1093/jbmr/zjaf123; https://doi.org/10.1093/jbmr/zjaf123 (econs2026fracturesarehighly pages 8-10)
Visual loss frequency in Chinese ADO2 cohort 1/36 (2.8%) 36 Chinese patients with ADO II 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 1-2)
Bone marrow failure frequency in Chinese ADO2 cohort 2/36 (5.6%) 36 Chinese patients with ADO II 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 1-2)
Key retrospective cohort size 36 patients; 28 unrelated families Single-center ADO II natural history study 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 2-3)
Longitudinal follow-up subset 15 patients; mean follow-up 6.3 years (range 1–14 years) Subset of the Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 1-2, wang2022naturalhistoryof pages 5-6)
New fractures during follow-up 5/15 Followed patients in Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6)
Baseline natural-history/biomarker cohort size 54 total (42 adults, 12 children); 37 adults with disease-causing CLCN7 variants Cross-sectional baseline analysis in ADO natural history study 2026 DOI: 10.1093/jbmr/zjaf123; https://doi.org/10.1093/jbmr/zjaf123 (econs2026fracturesarehighly pages 1-3)
Number of disease-causing CLCN7 mutations identified 21 mutations 36 Chinese ADO II patients 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 1-2)
Reported number of CLCN7 mutations in ADO overall >34 mutations reported Review summary 2024 Review URL not fully available in context (funckbrentanoUnknownyearppelmandikstranm pages 1-3)
Most frequent CLCN7 variant c.2299C>T (p.Arg767Trp), 16.2% (6 cases) Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 8-9, wang2022naturalhistoryof pages 1-2)
Phenotype of c.2299C>T (p.Arg767Trp) Joint discomfort/osteoarthritis common; 4/6 fractured, including 1 multiple fractures Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6)
Second recurrent CLCN7 variant c.296A>G (p.Tyr99Cys), 10.8% (4 cases) Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 8-9)
Phenotype of c.296A>G (p.Tyr99Cys) Fractures in 2 patients Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6)
Third recurrent CLCN7 variant c.857G>A (p.Arg286Gln), 10.8% (4 cases) Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 8-9)
Phenotype of c.857G>A (p.Arg286Gln) Mild symptoms; fewer fractures and lower FN/TH BMD Z-scores than p.Arg767Trp group Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 8-9)
Fourth recurrent CLCN7 variant c.937G>A (p.Glu313Lys), 8.1% (3 cases) Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 8-9, wang2022naturalhistoryof pages 1-2)
Phenotype of c.937G>A (p.Glu313Lys) Severe phenotype: severe fractures, visual loss, hematological defects, cranial palsy Chinese ADO II cohort 2022 DOI: 10.3389/fendo.2022.819641; https://doi.org/10.3389/fendo.2022.819641 (wang2022naturalhistoryof pages 5-6, wang2022naturalhistoryof pages 1-2)
Common variant in 2026 registry/natural-history cohort G215R most common (N=14 among CLCN7 variant carriers analyzed) Adult ADO natural-history/biomarker cohort 2026 DOI: 10.1093/jbmr/zjaf123; https://doi.org/10.1093/jbmr/zjaf123 (econs2026fracturesarehighly pages 8-10, econs2026fracturesarehighly pages 1-3)
Genotype–phenotype conclusion for G215R No significant difference vs other CLCN7 variants for fracture, BMD, or bone turnover markers Adult ADO natural-history/biomarker cohort 2026 DOI: 10.1093/jbmr/zjaf123; https://doi.org/10.1093/jbmr/zjaf123 (econs2026fracturesarehighly pages 1-3)

Table: This table compiles key quantitative data for autosomal dominant osteopetrosis type II, including incidence, penetrance, fracture burden, cohort sizes, and recurrent CLCN7 variants with associated phenotypes. It is useful as a quick evidence map for disease characterization and genotype-phenotype interpretation.


Visual evidence (radiographic and variant tables)

The ADO2 natural history cohort paper includes radiographic examples (sandwich vertebrae; bone-in-bone) and tables summarizing CLCN7 variants and their associated clinical/biochemical features (wang2022naturalhistoryof media 01f471f9, wang2022naturalhistoryof media 1e172433, wang2022naturalhistoryof media 154a27d0).


Recent developments and expert perspectives (2023–2024 emphasis)

  • 2024 adult osteopetrosis review (European expert perspective): emphasizes ADO2 as the common adult osteopetrosis subtype; highlights incomplete penetrance, high fracture burden with delayed repair, cranial nerve/dental complications, and recommends multidisciplinary specialized follow-up; also underscores evidence gaps in natural history and need for improved clinical studies/endpoints (funckbrentanoUnknownyearppelmandikstranm pages 1-3, funckbrentanoUnknownyearppelmandikstranm pages 3-4).
  • 2023 craniofacial/dental mechanisms review: reframes osteopetrosis diagnosis through “telltale” craniofacial/dental abnormalities and mechanistically groups causal genes (including CLCN7/TCIRG1/OSTM1) as controllers of osteoclastic acidification; recommends dental vigilance to reduce missed diagnoses (ma2023molecularmechanismsof pages 1-2, ma2023molecularmechanismsof pages 12-13).
  • 2023 genetics/pathogenesis review: stresses genotype-guided care, noting HSCT efficacy and contraindications depend on genetic subtype and neurologic involvement (nadyrshina2023clinicalgeneticaspects pages 2-3).

Evidence limitations (explicit)

  • Formal identifiers beyond MIM 166600, MONDO:0008156, and an osteopetrosis-category ICD-10-78.2 were not present in retrieved texts.
  • Recent (2023–2024) ADO2-specific prospective interventional trials were not retrieved; management evidence is predominantly expert review and cohort/case literature.
  • QoL instruments and population-level prevalence/incidence beyond estimates (1:20,000 births; 5.5/100,000 frequency cited) were not captured in the retrieved evidence set.

References

  1. (OpenTargets Search: autosomal dominant osteopetrosis type II,Albers-Schönberg disease-CLCN7): Open Targets Query (autosomal dominant osteopetrosis type II,Albers-Schönberg disease-CLCN7, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (funckbrentanoUnknownyearppelmandikstranm pages 1-3): T Funck-Brentano and MC Zillikens. Ppelman-di kstra, nm, & cohen-solal, m.(2024). Unknown journal, Unknown year.

  3. (funckbrentanoUnknownyearppelmandikstranm pages 3-4): T Funck-Brentano and MC Zillikens. Ppelman-di kstra, nm, & cohen-solal, m.(2024). Unknown journal, Unknown year.

  4. (kang2019acaseof pages 1-3): Sol Kang, Young Kyung Kang, Jun Ah Lee, Dong Ho Kim, and Jung Sub Lim. A case of autosomal dominant osteopetrosis type 2 with a <i>clcn7</i> gene mutation. Journal of Clinical Research in Pediatric Endocrinology, 11:439-443, Dec 2019. URL: https://doi.org/10.4274/jcrpe.galenos.2019.2018.0229, doi:10.4274/jcrpe.galenos.2019.2018.0229. This article has 8 citations.

  5. (nadyrshina2023clinicalgeneticaspects pages 2-3): D. D. Nadyrshina and R. I. Khusainova. Clinical, genetic aspects and molecular pathogenesis of osteopetrosis. Vavilov Journal of Genetics and Breeding, 27:383-392, Jul 2023. URL: https://doi.org/10.18699/vjgb-23-46, doi:10.18699/vjgb-23-46. This article has 13 citations.

  6. (wang2022naturalhistoryof pages 1-2): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.

  7. (nadyrshina2023clinicalgeneticaspects pages 1-2): D. D. Nadyrshina and R. I. Khusainova. Clinical, genetic aspects and molecular pathogenesis of osteopetrosis. Vavilov Journal of Genetics and Breeding, 27:383-392, Jul 2023. URL: https://doi.org/10.18699/vjgb-23-46, doi:10.18699/vjgb-23-46. This article has 13 citations.

  8. (ma2023molecularmechanismsof pages 2-4): Yu Ma, Yali Xu, Yanli Zhang, and Xiaohong Duan. Molecular mechanisms of craniofacial and dental abnormalities in osteopetrosis. International Journal of Molecular Sciences, 24:10412, Jun 2023. URL: https://doi.org/10.3390/ijms241210412, doi:10.3390/ijms241210412. This article has 21 citations.

  9. (wang2022naturalhistoryof pages 8-9): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.

  10. (econs2026fracturesarehighly pages 1-3): Michael J Econs, Stuart J Warden, Ziyue Liu, Paul J Niziolek, Corinne Parks-Schenck, Netsanet Gebregziabher, Rita L Gerard-O'Riley, Marian Hart, Lynda E Polgreen, and Erik A Imel. Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis. Journal of Bone and Mineral Research, 41:150-157, Sep 2026. URL: https://doi.org/10.1093/jbmr/zjaf123, doi:10.1093/jbmr/zjaf123. This article has 0 citations and is from a highest quality peer-reviewed journal.

  11. (ma2023molecularmechanismsof pages 8-10): Yu Ma, Yali Xu, Yanli Zhang, and Xiaohong Duan. Molecular mechanisms of craniofacial and dental abnormalities in osteopetrosis. International Journal of Molecular Sciences, 24:10412, Jun 2023. URL: https://doi.org/10.3390/ijms241210412, doi:10.3390/ijms241210412. This article has 21 citations.

  12. (wang2022naturalhistoryof pages 5-6): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.

  13. (funckbrentanoUnknownyearppelmandikstranma pages 4-5): T Funck-Brentano and MC Zillikens. Ppelman-di kstra, nm, & cohen-solal, m.(2024). Unknown journal, Unknown year.

  14. (ma2023molecularmechanismsof pages 1-2): Yu Ma, Yali Xu, Yanli Zhang, and Xiaohong Duan. Molecular mechanisms of craniofacial and dental abnormalities in osteopetrosis. International Journal of Molecular Sciences, 24:10412, Jun 2023. URL: https://doi.org/10.3390/ijms241210412, doi:10.3390/ijms241210412. This article has 21 citations.

  15. (ma2023molecularmechanismsof pages 12-13): Yu Ma, Yali Xu, Yanli Zhang, and Xiaohong Duan. Molecular mechanisms of craniofacial and dental abnormalities in osteopetrosis. International Journal of Molecular Sciences, 24:10412, Jun 2023. URL: https://doi.org/10.3390/ijms241210412, doi:10.3390/ijms241210412. This article has 21 citations.

  16. (wang2022naturalhistoryof pages 2-3): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.

  17. (funckbrentanoUnknownyearppelmandikstranm pages 4-5): T Funck-Brentano and MC Zillikens. Ppelman-di kstra, nm, & cohen-solal, m.(2024). Unknown journal, Unknown year.

  18. (basit2026geneticsofosteopetrosis pages 8-9): Sulman Basit and Khalid I. Khoshhal. Genetics of osteopetrosis: molecular insights and clinical implications. Journal of Musculoskeletal Surgery and Research, 10:40-50, Nov 2026. URL: https://doi.org/10.25259/jmsr_357_2025, doi:10.25259/jmsr_357_2025. This article has 0 citations.

  19. (funckbrentanoUnknownyearppelmandikstranma pages 3-4): T Funck-Brentano and MC Zillikens. Ppelman-di kstra, nm, & cohen-solal, m.(2024). Unknown journal, Unknown year.

  20. (econs2026fracturesarehighly pages 8-10): Michael J Econs, Stuart J Warden, Ziyue Liu, Paul J Niziolek, Corinne Parks-Schenck, Netsanet Gebregziabher, Rita L Gerard-O'Riley, Marian Hart, Lynda E Polgreen, and Erik A Imel. Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis. Journal of Bone and Mineral Research, 41:150-157, Sep 2026. URL: https://doi.org/10.1093/jbmr/zjaf123, doi:10.1093/jbmr/zjaf123. This article has 0 citations and is from a highest quality peer-reviewed journal.

  21. (wang2022naturalhistoryof media 01f471f9): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.

  22. (wang2022naturalhistoryof media 1e172433): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.

  23. (wang2022naturalhistoryof media 154a27d0): Ziyuan Wang, Xiang Li, Ya Wang, Wenzhen Fu, Yujuan Liu, Zhenlin Zhang, and Chun Wang. Natural history of type ii autosomal dominant osteopetrosis: a single center retrospective study. Frontiers in Endocrinology, Mar 2022. URL: https://doi.org/10.3389/fendo.2022.819641, doi:10.3389/fendo.2022.819641. This article has 13 citations.